Encorafenib plus binimetinib combined BRAF-MEK inhibitors



Trial Studied treatment Control Patients Size Study type Results NCT

Melanoma - combined BRAF-MEK inhibitors in all type of patients - B-Raf enzyme inhibitors in all type of patients - MEK inhibitor in all type of patients

COLUMBUS, 2018encorafenib plus binimetinibvemurafenib1L383 (192/191) NCT01909453



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons